Useful serum biomarkers would be helpful to evaluate the ILD deterioration and predict prognosis for patients with anti‐MDA5 positive DM/CADM‐related ILD (MDA5‐DM/CADM‐ILD). Here, IFIH1 is linked to clinically amyopathic dermatomyositis.